Delivery Order SPE2DX15D8003-SPE2DX24F7E4E
Award Date
6/27/24
Potential Completion Date
6/28/24
Potential Value
$10K
Federal Agency
Medical Supply Chain
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of 4567372217 ! DUPIXENT 300 MG/2 ML PEN 2ML. The contract has a ceiling value of $4,755.09 and a period of performance extending through February 26, 2025. The contract is not designated as a set-aside. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, with a ceiling value of $7,211.74, is for the delivery of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has an ultimate completion date of June 6, 2024. Dakota Drug, Inc. is a key supplier for the DLA, holding a significant single-award Indefinite Delivery Contract...
This is a federal contract award by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,722.06 Firm Fixed Price Delivery Order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract has an ultimate completion date of February 5, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to provide a...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $2,673.87 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4567655331 DUPIXENT 300 MG/2 ML PEN 2ML. This contract has an ultimate completion date of March 24, 2025 and was awarded on March 21, 2025. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and...
This is a delivery order issued under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical division. The contract was awarded to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The fixed-price delivery order has a ceiling value of $8,901.48 and a period of performance through May 30, 2024. Dakota Drug, Inc. holds a significant single-award IDC with...
The Defense Logistics Agency (DLA) awarded a $5,601.75 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. This contract, which does not have a set-aside designation, is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Dakota Drug, Inc. holds with the DLA Troop Support Medical's ECAT Generation V Program, which procures commercial medical...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the procurement of DUPIXENT 300 MG/2 ML PEN 2ML medical supplies. The contract, valued at $13,423.69, has an ultimate completion date of March 7, 2025. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S....
This is a firm fixed-price delivery order contract awarded to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Medical Supply Chain division. The contract, valued at $6,278.19, is for the delivery of 200 mg/1.14 ml DUPIXENT pens to support U.S. Armed Forces medical operations. The contract has a period of performance through November 3, 2023 and is not a set-aside award. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC)...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $11,049.12 firm fixed-price delivery order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML medical products. This award is part of Dakota Drug's existing $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, SPE2DB24D8001, under the ECAT Generation V Program. The contract has a period of...
This is a $10,142.13 firm fixed-price delivery order awarded on November 30, 2023 by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of 4562954307 DUPIXENT 300 MG/2 ML SYRINGE 2ML. The award has an ultimate completion date of December 1, 2023 and is not a set-aside contract. Dakota Drug, Inc. is a key pharmaceutical and medical supply vendor for the DLA, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) for the DLA...